[2026] Participation in the 9th Neuroscience Forum on Alzheimer's Disease (NFAD)

Bredis Healthcare participated in the 9th Neuroscience Forum on Alzheimer's Disease (NFAD), held on February 6, 2026, at the L7 Chungjang by Lotte in Gwangju.

Under the theme “A Paradigm Shift in Overcoming Dementia: Blood Diagnostics, Innovative Treatments, and AI,” the forum featured a total of nine symposia that focused on sharing the latest research findings and clinical experiences in the fields of Alzheimer’s disease and dementia. A wide range of topics were covered, including the clinical application of blood-based biomarkers, the latest trends in anti-amyloid immunotherapies, AI and digital diagnostic technologies, and research on neuroinflammation and lysosomal pathology, leading to in-depth discussions among industry, academia, research institutes, and hospitals aimed at overcoming dementia.

In particular, Hwang Hyun-doo, CEO of Bredis Healthcare, delivered a lecture titled “Beyond Digital Immunoassay: Introducing NULISA, a New Era of Ultrasensitive Proteomics,” introducing the innovative potential of NULISA—a next-generation, ultra-sensitive proteomics technology that surpasses existing digital immunoassays—to a panel of experts.

At a time when blood biomarker-based diagnostic technology is emerging as a key to overcoming dementia, this was a meaningful occasion for Bredis Healthcare to present a new technological paradigm at the forefront of this field.